Related coverage linked through entity extraction aliases.
Apr 06, 2026
The 2026 Tandem Meetings featured new data on CAR-T, allogeneic transplantation, and supportive care. Highlights included early efficacy signals for EB-103, KITE-753, Orca-T, and NXC-201, plus comparative cardiovascular safety data for lisocabtagene maraleucel.
Mar 06, 2026
A Phase 1 trial of azer-cel, a CAR T-cell therapy using donor T-cells to target B-cells, is recruiting patients with progressive multiple sclerosis at eight U.S. sites. Separately, multiple randomized trials are comparing hematopoietic stem cell transplantation against high-efficacy disease-modifying therapies.
Feb 28, 2026
Researchers develop multiple strategies to enhance CAR T-cell therapy, including dual PGE2 receptor knockout for solid tumors and small-molecule switches using venetoclax and caffeine to control cellular activity and improve safety.
Feb 18, 2026
Pluri Inc. receives patent grant from China National Intellectual Property Administration for its proprietary 3D immune cell expansion and activation technology, expanding global IP protection across U.S., China, Japan, Korea, Australia and Israel.
